Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
Submitted by
admin
on July 26, 2017 - 10:36pm
Source:
Fierce Pharma
News Tags:
Amgen
biosimilars
M&A
Headline:
With $39B in cash and biosim threats looming, could Amgen use a deal? Executives say not yet
Do Not Allow Advertisers to Use My Personal information
